

3-((6-chloro-2-cyclopropyl-1-(1-(ethyl-*d*₅)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 1-127);

3-((2,6-dichloro-1-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 1-31);

3-((2,6-dichloro-7-fluoro-1-(pyridin-3-yl)-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 2-1);

3-((2-bromo-6-chloro-7-fluoro-1-(pyridin-3-yl)-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 2-2);

3-((6-chloro-2-cyclopropyl-7-fluoro-1-(pyridin-3-yl)-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 2-3);


3-((1-(1-(6-aminoethyl)-1*H*-pyrazol-4-yl)-6-chloro-2-cyclopropyl-7-fluoro-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 1-128);

3-((6-chloro-2-cyclopropyl-7-fluoro-1-(1-(hex-5-yn-1-yl)-1*H*-pyrazol-4-yl)-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 1-129);

3-((1-(1-(3-hydroxy-2,2-dimethylpropyl)-1*H*-pyrazol-4-yl)-6-chloro-2-cyclopropyl-7-fluoro-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound no. 1-130); or

3-((6-chloro-2-cyclopropyl-1-(1-(6-(3-(3',6'-dihydroxy-3-oxo-3*H*-spiro[isobenzofuran-1,9'-xanthen]-5-yl)ureido)hexyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-indol-3-yl)thio)-2-fluorobenzoic acid (Compound 1-131).

[0079a] In one aspect, described herein is a compound that has the following structure, or a pharmaceutically acceptable salt, or solvate thereof:



wherein,

W is, CF or N;

R^A is H, halogen, -CN, -OH, -OR⁹, -SR⁹, C₁-C₆alkyl, or C₁-C₆fluoroalkyl;

R⁹ is C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, or C₃-C₆cycloalkyl;

R^B is H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;

L¹ is absent, C₁-C₆alkylene, or C₃-C₆cycloalkylene;

R² is halogen, -CN, -OH, C₁-C₄alkyl, C₁-C₄fluoroalkyl, C₁-C₄deuteroalkyl, C₁-C₄alkoxy, or C₁-C₄fluoroalkoxy; and

R³ is halogen, -CN, -OH, C₁-C₄alkyl, C₁-C₄fluoroalkyl, C₁-C₄deuteroalkyl, C₁-C₄alkoxy, or C₁-C₄fluoroalkoxy.

[0079b] In one aspect, described herein is a compound that is: 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid; or a pharmaceutically acceptable salt, or solvate thereof.

[0079c] In one aspect, described herein is a compound that is: 3-((2,6-dichloro-7-fluoro-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid; or a pharmaceutically acceptable salt, or solvate thereof.

[0079d] In one aspect, described herein is a compound that is: 3-((2,6-dichloro-1-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-indol-3-yl)thio)-2-fluorobenzoic acid; or a pharmaceutically acceptable salt, or solvate thereof.

[0080] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.


[0081] In one aspect, described herein is a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.

[0082] In one aspect, described herein is a method of treating or preventing any one of the diseases or conditions described herein comprising administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt, or solvate thereof, to a mammal in need thereof.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound that has the following structure, or a pharmaceutically acceptable salt, or solvate thereof:



wherein,

W is, CF or N;

R^A is H, halogen, -CN, -OH, -OR⁹, -SR⁹, C₁-C₆alkyl, or C₁-C₆fluoroalkyl;

R⁹ is C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, or C₃-C₆cycloalkyl;

R^B is H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;

L¹ is absent, C₁-C₆alkylene, or C₃-C₆cycloalkylene;

R² is halogen, -CN, -OH, C₁-C₄alkyl, C₁-C₄fluoroalkyl, C₁-C₄deuteroalkyl, C₁-C₄alkoxy, or C₁-C₄fluoroalkoxy; and

R³ is halogen, -CN, -OH, C₁-C₄alkyl, C₁-C₄fluoroalkyl, C₁-C₄deuteroalkyl, C₁-C₄alkoxy, or C₁-C₄fluoroalkoxy.

2. The compound of claim 1, or a pharmaceutically acceptable salt, or solvate thereof, wherein:
 R^A is H, F, Cl, Br, I, -CN, -OH, -OCH₃, -OCH₂CH₃, -OCF₃, -OCH₂CF₃, -CH₃, -CH₂CH₃, -CF₃, or -CD₃.
3. The compound of claim 2, or a pharmaceutically acceptable salt, or solvate thereof, wherein:
 R^B is C₁-C₆alkyl.
4. The compound of claim 3, or a pharmaceutically acceptable salt, or solvate thereof, wherein:
 R^2 is F, Cl, Br, I, -CN, -OH, -CH₃, -CF₃, -CD₃, -OCH₃, -OCH₂CH₃, -OCF₃, or -OCH₂CF₃; and
 R^3 is F, Cl, Br, I, -CN, -OH, -CH₃, -CF₃, -CD₃, -OCH₃, -OCH₂CH₃, -OCF₃, or -OCH₂CF₃.
5. The compound of claim 4, or a pharmaceutically acceptable salt, or solvate thereof, wherein:
 R^2 is Cl; and
 R^3 is F, or Cl.
6. The compound of claim 5, or a pharmaceutically acceptable salt, or solvate thereof, wherein: L^1 is absent, -CH₂-, -CH(CH₃)-, -C(CH₃)₂-, or cyclopropyl-1,1-diyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt, or solvate thereof, wherein:
 L^1 is absent.
8. The compound of claim 1, wherein the compound is:
3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio-)-2-fluorobenzoic acid;
3-((2,6-dichloro-7-fluoro-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio-)-2-fluorobenzoic acid; or
3-((2,6-dichloro-1-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-indol-3-yl)thio-)-2-fluorobenzoic acid;
or a pharmaceutically acceptable salt, or solvate thereof.

9. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.
10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration.
11. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
12. A compound that is:
3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid;
or a pharmaceutically acceptable salt, or solvate thereof.
13. A pharmaceutical composition comprising a compound of claim 12, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.
14. A compound that is:
3-((2,6-dichloro-7-fluoro-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid;
or a pharmaceutically acceptable salt, or solvate thereof.

15. A pharmaceutical composition comprising a compound of claim 14, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.

16. A compound that is:

3-((2,6-dichloro-1-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-indol-3-yl)thio)-2-fluorobenzoic acid;

or a pharmaceutically acceptable salt, or solvate thereof.

17. A pharmaceutical composition comprising a compound of claim 16, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.